Cargando…
Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox
Hormone receptor testing mainly serves the purpose of guiding treatment choices for breast cancer patients. Patients with estrogen receptor (ER)‐positive breast cancers show significant response to endocrine therapy. However, the methods to define ER status and eligibility for treatment remain contr...
Autores principales: | Yu, Ke‐Da, Cai, Yu‐Wen, Wu, Song‐Yang, Shui, Ruo‐Hong, Shao, Zhi‐Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504145/ https://www.ncbi.nlm.nih.gov/pubmed/34251757 http://dx.doi.org/10.1002/cac2.12191 |
Ejemplares similares
-
De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort
por: Cai, Yu‐Wen, et al.
Publicado: (2022) -
Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015) -
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018) -
Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis
por: Cai, Yu-Wen, et al.
Publicado: (2022) -
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
por: Shao, Wenlin, et al.
Publicado: (2004)